Apixaban (Eliquis) for the prevention of venous thromboembolic events

For the prevention of venous thromboembolic events in adults after a hip or knee replacement operation apixaban has an added therapeutic value in comparison with coumarins, LMWH’s and fondaparinux. The therapeutic value of apixaban is comparable with that of rivaroxaban.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.